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STAT4 variants increase liver fibrosis risk in chronic hepatitis B through impaired STAT4-
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Abstract (N=223 words) 
Host genetic modifiers of the natural history of chronic hepatitis B (CHB) infection remains poorly 
understood. Recently, a GWAS identified polymorphism in the STAT4 gene that contributes to the risk 
for hepatocellular carcinoma (HCC) was shown to be associated with the full spectrum of HBV 
outcomes in Asian patients. However, the functional mechanisms for this effect are unknown and the 
role of the variant in modulating HBV disease in Caucasians has not been investigated. We determined 
whether STAT4 genetic variation is associated with liver injury and investigated for potential 
mechanisms mediating this effect in Caucasians with CHB. In 1085 subjects (830 with CHB and 255 
healthy controls), STAT4 rs7574865 genotype was independently associated with hepatic inflammation 
(OR: 1.42, 95% CI: 1.07-2.06, p=0.02) and advanced fibrosis (OR: 1.83, 95% CI: 1.19-2.83, p=0.006). 
The minor allele frequency (MAF) of rs7574865 was significantly lower than that in healthy controls, 
suggestive of an association between STAT4 variants and HBV persistence. rs7574865 GG risk carriers 
expressed lower levels of STAT4 in liver and in PBMCs, while NK cells from patients with the 
rs7574865 GG genotype had impaired STAT4 phosphorylation following stimulation with IL-12/IL-18 
and a reduction in secretion of the anti-fibrotic cytokine interferon-gamma (IFN-γ). Conclusion: 
Genetic susceptibility to HBV persistence, hepatic inflammation and fibrosis in Caucasians associates 
with variation in STAT4 at the rs7574865 locus. Downstream effects on NK cell function through 




 Two billion people worldwide have been exposed to the hepatitis B virus (HBV) of whom ~350 
million are chronically infected, with 800,000 deaths annually from complications 1. HBV is not 
directly cytopathic to hepatocytes, with liver damage a consequence of the host immune response 
directed towards eliminating the virus 2. A complex interplay between the immune response, viral and 
host genetic factors, shapes the final outcome of infection 3.  
 One of the host mechanisms mediating HBV activity appears to be JAK-STAT-signaling. This 
pathway plays a critical role in viral clearance on the one hand, and hepatic inflammation and fibrosis 
on the other 4, 5. This is not unexpected since STAT4, a member of the STAT (signal transducers and 
activators of transcription) protein family is activated by diverse cytokines including interleukin-12 and 
interferon alpha (IFN-α) in response to viral infections 6 to regulate tissue inflammation, fibrosis, and 
antiviral activities 7. The precise role of STAT4 in the pathogenesis of liver injury is largely unknown, 
but data from STAT4 knockout mice suggest context-dependent effects with mice being more 
susceptible to acute T-cell hepatitis 8, while having equal liver injury after ischemia/reperfusion 9. 
 The host genetic milieu is an important contributor to the risk of HBV persistence and 
progression as reviewed elsewhere 10. Recently, a single nucleotide polymorphism (SNP), rs7574865 in 
the third intron of the STAT4 gene was reported to be associated with the entire spectrum of HBV 
infection including spontaneous clearance, response to IFN-α based therapy and the risk of HBV-
related cirrhosis and hepatocellular carcinoma (HCC), with risk conferred by the GG genotype 11-14 in 
Asian patients. The role of this variant in other HBV-infected populations and the effect size, if any, is 
still unknown. Furthermore, how this variant functionally contributes to HBV pathogenesis and 
outcomes is not understood.  
 We recently reported that rs7574865 does not play any role in either the response to interferon-
based treatment, spontaneous clearance or fibrosis progression in Caucasian patients with chronic 
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hepatitis C 15. Whether this lack of association is due to ethnic differences or more likely to differences 
in the hepatic immune response to HBV and HCV is unknown, but intriguing. Understanding this 
dichotomy is important because unravelling differential immune pathways related to viral clearance 
and liver injury will enhance our understanding of disease pathogenesis 10. The aim of this study was to 
examine the effect of STAT4 rs7574865 variation to liver injury in Caucasian patients with CHB and to 







 The study comprised 1085 subjects (830 histologically characterized Caucasian CHB patients 
and 255 healthy Caucasian controls). All consecutive patients who had detectable hepatitis B surface 
antigen (HBsAg), persistently or intermittently abnormal alanine aminotransferase (ALT) values and 
serum HBV DNA >2,000 IU/mL for >6 months with at least one liver biopsy prior to any therapy were 
included. Patients were excluded if they had evidence of co-infection with either hepatitis C virus 
(HCV), hepatitis delta virus (HDV) or human immunodeficiency (HIV) virus, were diagnosed with or 
suspected to have HCC or alpha-fetoprotein >100 ng/mL, or had evidence of other liver diseases by 
standard tests. Patients with a current or previous episode of hepatic decompensation defined as (i) 
ascites (overt or by ultrasound), (ii) hepatic encephalopathy (HE), (iii) gastroesophageal variceal 
bleeding (GEVB), (iv) jaundice or (v) hepatorenal syndrome (HRS) were excluded. The healthy 
Caucasian control group was enrolled at Westmead hospital and has been described previously 16. 
These patients reported no history of chronic liver disease and did not abuse alcohol (< 20 gm of 
alcohol daily). Ethics approval was obtained from the Human Research Ethics Committees of the 
Sydney West Local Health District and the University of Sydney. All other sites had ethics approval 
from their respective ethics committees. Written informed consent for genetic testing was obtained 
from all participants.  
Clinical and laboratory assessment 
 The following data were collected at time of liver biopsy from all patients: gender, age, 
ethnicity, recruitment center, body mass index (BMI), HBV-DNA level, HBe-Ag status and routine 




 Liver histopathology was scored by expert pathologists according to METAVIR17. Fibrosis was 
staged from F0 (no fibrosis) to F4 (cirrhosis). Necroinflammation (A) was graded as A0 (absent), A1 
(mild), A2 (moderate), or A3 (severe). The inter-observer agreement between pathologists was studied 
previously and was good (κ = 77.5) for METAVIR staging using κ statistics 18.   
Genotyping 
 Genotyping for STAT4 rs7574865 was undertaken using the TaqMan SNP genotyping allelic 
discrimination method (Applied Biosystems, Foster City, CA, USA). Genotyping was blinded to 
clinical variables.  
Cell culture and HBV Transfection  
 Huh7 cells lines were incubated in Dulbecco's modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) at 37°C and 5% CO2. To examine the effect of HBV on STAT4 
expression, 6-well plates were seeded with 5 × 105 Huh7 cells. On the next day, cells were transiently 
transfected with an HBV expressing plasmid (wild type HBV, genotype D) using the Fugene 
transfection reagent (Promega) and harvested 72 hours later. Transfection efficiency was evaluated 
using the Great EscAPe secreted alkaline phosphatase reporter system 3 (Clontech) in which 10 ng/ml 
of a reporter plasmid expressing secreted alkaline phosphatase (SEAP) is co-transfected. Experiments 
were performed at least in triplicate. 
Quantitative real time reverse transcription PCR 
 To determine the functional effects of STAT4 rs7574865, we examined for the association of 
hepatic and peripheral blood mononuclear cell (PBMC) STAT4 expression according to STAT4 
rs7574865 genotype in a cohort of 45 liver biopsies from CHB patients having stored liver tissue 
available for analysis as described previously 19, and in PBMCs from healthy controls (n=30). EDTA 
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tubes of blood were collected from healthy participants and separated on Ficoll-Paque to obtain 
PBMCs.  
STAT4 mRNA expression was also assessed in human primary hepatocytes, human primary hepatic 
stellate cells, human primary hepatic sinusoidal endothelial cells (ScienceCell) and human primary 
Kupffer cells (Thermofisher). mRNA expression levels were determined using TaqMan probes and 
master mix (Life Technologies) according to the manufacturer’s protocol. RNA was extracted using the 
RNeasy kit (Qiagen) according to the manufacturer’s instructions. RNA quality and concentration was 
assessed using the Agilent 2100 Bioanalyser (Agilent, Waldbronn, Germany). cDNA was prepared 
using qscript (Quanta Biosciences, Gaithersburg, MD, USA) in a Mastercycler gradient 5331 
(Eppendorf AG, Hamburg, Germany). GAPDH was used as the house keeping gene. Expression was 
measured using CT values, normalized to that of GAPDH (ΔCT= CT (GAPDH) - CT (target) and then 
expressed as 2ΔCT .  
Intracellular pSTAT4 assay 
 Frozen PBMCs were thawed and incubated with or without IL-12 (10 ng/mL; R&D Systems) 
plus IL-18 (100 ng/mL R&D Systems) for 10 minutes at 37ºC. pSTAT4 was measured using the 
Phosflow kit (BD Biosciences) according to the manufacturer's protocol. Briefly, cells were fixed in 
fixation buffer and then stained with anti-CD56-BU737 (BD Biosciences) and anti-human CD19 
APC/CY7(biolegend) to identify NK cells and B cells, respectively, and with anti-CD3-pacific blue 
(BD Biosciences) to exclude T cells. Cells were then permeabilized with Perm III buffer (BD 
Biosciences), blocked with 10 % goat block buffer and additionally stained with anti-STAT4 (Abcam), 
or anti-pSTAT4-Alexa, Fluor647 (BD Biosciences). Stained cells were analyzed with FACScan 
(Becton Dickinson, Mountain View, CA, USA) LSRII and the data processed using the Flow-Jo 




Frozen PBMCs were thawed and incubated with or without IL-12 (1 ng/mL; R&D Systems) 
plus IL-18 (100 ng/mL R&D Systems) for 14 hours, followed by the addition of brefeldin A for 4 hours 
and stained for intracellular IFN-γ. For confirmation, levels of IFN-γ were measured using Ready-Set-




 Data are shown as mean and standard deviation (SD), median and range or number and 
proportion as appropriate. The distribution of STAT4 rs7574865 genotypes between the different 
groups was compared using Fisher’s exact test. The Cochran–Armitage test was used for assessment of 
trend. The Student’s t-test or non-parametric, i.e. Wilcoxon-Mann-Whitney U-test or Kruskal-Wallis 
tests were used to compare quantitative data, as appropriate. All tests were two-tailed and p values 
<0.05 were considered significant. For rs7574865, a recessive model (GG versus GT/TT) was adopted 
as reported previously in the literature 11, 12. Hardy-Weinberg equilibrium tests of STAT4 rs7574865 in 
patients were performed using the chi squared test. 
 Binary logistic regression was used to evaluate the effect of STAT4 rs7574865 on significant 
fibrosis (METAVIR score F2-4) and included other risk factors (age, gender, BMI, HBV-DNA and 
recruitment centre). The odds ratio estimates the relative change in the rate of the outcome per unit 
increase in the explanatory variable. HBV-DNA levels were log-transformed before entry into the 
model. Results are expressed as odds ratios and 95% confidence intervals (CI). Statistical analyses 





 The demographic, biochemical, and virologic characteristics of the studied CHB patients are 
presented in Supplementary Table 1. The median age was 45 years and 72% were male. 384 (46%) 
patients had moderate to severe inflammation (A2-A3) and 281 (34%) had advanced fibrosis 
(METAVIR score F3-4). 
STAT4 rs7574865 minor allele frequency in the HBV cohort  
 The genotype distribution of STAT4 rs7574865 in CHB patients and in the healthy Caucasian 
population is shown in Supplementary Table 2. Genotype distribution was in Hardy-Weinberg 
equilibrium in both groups (p=0.6 and 0.9, respectively). The minor allele (T) frequency (MAF) of 
rs7574865 was 0.19, significantly lower than that observed in a reference Caucasian population sample 
(MAF 0.23, http://browser.1000genomes.org) 20 and in our healthy cohort (MAF 0.24) (χ2 for 
trend=p=0.04). This data is supportive for an association between STAT4 variation and persistent HBV 
infection.  
Association of STAT4 rs7574865 genotype with clinical variables  
 Next, we explored if baseline clinical variables differed between CHB patients according to 
STAT4 rs7574865 genotype; the results are presented in Supplementary Table 3. There was no 
evidence of significant association between rs7574865 genotype (GG versus GT/TT) and any of the 
clinical variables (i.e. age, BMI, baseline levels of ALT, AST, GGT, bilirubin, albumin  or HBV DNA, 
gender frequency, HBe-Ag status and diabetes status). 
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STAT4 rs7574865 genotype and severity of hepatic inflammation  
 We assessed the association of rs7574865 with hepatic inflammation. The distribution of 
rs7574865 genotypes according to hepatic inflammation is depicted in Figure 1A. In multivariate 
ordinal regression analysis adjusted for covariates including age, gender, BMI, recruitment centre and 
viral load, rs7574865 was associated with the severity of necroinflammation (β=0.097±0.041, p=0.01) 
(Supplementary Table 4). In further analysis subdividing the cohort into those with mild (A0–1) 
versus severe hepatic inflammation (A2–A3), again the rs7574865 GG genotype was associated with 
severe hepatic inflammation by multiple logistic regression analysis adjusting for the same variables 
(OR: 1.42, 95% CI: 1.07-2.06, p=0.02) (Table 1).  
STAT4 rs7574865 genotype and stage of liver fibrosis 
 
 We assessed the association of rs7574865 with fibrosis stage. The distribution of rs7574865 
genotypes according to hepatic fibrosis is depicted in Figure 1B.  In multivariate ordinal regression 
analysis adjusted for the covariates mentioned above, rs7574865 was associated with the severity of 
fibrosis (β=0.114±0.043, p=0.005) (Supplementary Table 4). In further multiple logistic regression 
analysis adjusting for the same variables after subdividing the cohort into those without advanced 
fibrosis (F0–F2) versus those with advanced fibrosis (F3–F4), rs7574865 GG genotype associated with 
F3-F4 fibrosis (OR: 1.83, 95% CI: 1.19-2.83, p=0.006) (Table 1).  
STAT4 expression is decreased in HBV infected patients and in HBV-expressing cells 
 
 To explore the role of STAT4 in HBV pathogenesis, we first determined hepatic expression of 
STAT4 in patients with chronic HBV and in healthy controls using RT-PCR. HBV-infected patients 
exhibited significantly lower hepatic levels of STAT4 than healthy subjects (p<0.0001) (Figure 2A). 
To further investigate the association, we examined the expression of STAT4 in Huh-7 cells transiently 
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transfected with an HBV plasmid (wild type HBV, genotype D); RT-PCR was used to quantify 
expression (Figure 2B). Consistently, STAT4 mRNA levels after HBV-transfection was decreased 
compared to control uninfected cells transfected with SEAP expressing plasmid (Figure 2C). Thus, 
STAT4 expression is decreased during HBV infection and in cells transfected with an HBV plasmid. 
Hepatic STAT4 is negatively correlates with markers of liver injury and inflammation  
 Based on the finding that hepatic expression of STAT4 is reduced in patients with chronic 
HBV, we explored the impact of disease progression on STAT4 expression and correlated the latter 
with clinical parameters. According to the Metavir inflammation/activity grade, patients with 
significant hepatic inflammation (A2-A3) had lower STAT4 mRNA levels than those with none or 
mild inflammation (A0–A1) (Figure 2D). Negative correlations were also found between hepatic 
STAT4 and several biochemical parameters of liver injury, including AST (r=-0.43, p=0.004) and ALT 
(r=-0.32, p=0.03) by Spearman’s rank correlation. No significant correlation was observed with age, 
gender, BMI, Platelets, albumin, HB-DNA levels, HBe-Ag status or fibrosis stage.  
 To further tease out the STAT4 data from liver, we investigated STAT4 expression in primary 
human hepatocytes, Kupffer cells, hepatic sinusoidal endothelial cells and hepatic stellate cells by 
ultrasensitive droplet digital PCR (ddPCR). The highest expression of STAT4 was observed in Kupffer 
cells followed by hepatocytes, while stellate cells and sinusoidal cells had low expression (Figure 2E). 
Expression of STAT4 was also low in the human hepatic stellate cell line (LX2 cells), in both freshly 
plated and 1 day culture activated cells (threshold cycle=32) and was not significantly altered in 
response to the archetypal profibrotic cytokine (TGF-β) (data not shown). In total, these data suggest 
that the effect of STAT4 on liver inflammation is likely mediated by immune cells rather than direct 
effects on stellate cells. 
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STAT4 expression in liver is rs7574865 genotype dependent 
 To investigate potential mechanisms of rs7574865 function and given the intronic location of 
rs7574865, we considered that STAT4 expression might be modulated in an rs7574865 genotype–
specific manner. To examine for this, we measured mRNA levels of STAT4 in liver biopsies from 
individuals with CHB (n=45) using quantitative RT-PCR stratified according to rs7574865 genotype.  
In this analysis, patients with the risk genotype GG at rs7574865 had lower mRNA levels of STAT4, 
compared to patients with the GT/TT genotype (p< 0.05) (Figure 3A). 
rs7574865 regulates induction of pSTAT4 in NK Cells 
 To avoid the confounding effects of a chronic inflammatory state and/or disease fluctuation in 
HBV patients, we studied the impact of the risk genotype on STAT4 expression in a healthy 
population. To do this, we isolated PBMCs from healthy subjects and STAT4 expression was 
quantified by real-time PCR (n=30). As expected, STAT4 mRNA expression was reduced in subjects 
with the rs7574865 risk GG genotype compared to those with GT/TT genotypes (p< 0.05) (Figure 3B).  
 Next, we measured intracellular STAT4 protein by flow cytometry. Because NK cells are major 
contributors to innate IFN-γ production, and activation of STAT4 is important for peak responses 21, 
we focussed on these cells. Under basal (unstimulated) conditions, no difference in total STAT4 protein 
levels was observed between subjects with rs7574865 GG versus GT/TT genotypes (Figure 3C). We 
then reassessed STAT4 phosphorylation following stimulation of PBMCs with IL-12 plus IL-18; the 
CD56 NK cell population was studied by flow cytometry. After stimulation, there was significantly 
lower STAT4 phosphorylation in subjects with rs7574865 GG, compared to subjects with the GT/TT 
genotypes (p< 0.05) (Figure 3D). These data suggest reduced STAT4 activity in the risk rs7574865 
GG genotype that is associated with increased hepatic inflammation and fibrosis. 
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IFN-γ Production by NK Cells is STAT4 rs7574865 genotype dependent 
 IFN-γ has well known anti-fibrotic effects mediated via inhibition of HSC activation and 
enhancement of NK cell cytotoxic activity towards HSCs 22. IFN-γ also contributes to HBV clearance 
23. The ability of NK cells to produce IFN-γ in response to IL-12 is dependent on STAT4 
phosphorylation 24. Therefore, to evaluate whether IFN-γ secretion by NK cells is STAT4 rs7574865 
genotype dependent and thus may ultimately lead, in the appropriate context, to genotype-dependent 
effects on fibrosis. To this end, PBMCs were stimulated with IL-12 and IL-18 and the CD56 NK cell 
population was studied by flow cytometry. As shown in Figure 4A, consistent with the decrease in ex 
vivo pSTAT4 in subjects with the rs7574865 GG risk genotype, there was a decrease in the percentage 
of IFN-γ production by NK cells. The latter was confirmed by ELISA for IFN-γ secretion in the 





 We have demonstrated that the GG genotype at rs7574865 in the STAT4 gene confers 
susceptibility to more severe liver injury and fibrosis in a large cohort of Caucasian patients with 
chronic hepatitis B. Individuals with this genotype also appear more likely to develop chronic HBV 
infection. Finally, we show that those with the risk GG genotype have lower STAT4 mRNA expression 
in liver and PBMCs, while their NK cells display decreased pSTAT4 upon in vitro stimulation with IL-
12 and IL-18, with consequent functional deficiency in STAT4 dependent IFN-γ production. This 
model is summarized in a schematic Figure 5. 
 The rs7574865 polymorphism was originally identified by GWAS as a risk variant for HBV 
associated HCC in Chinese patients when compared to those with HBV and no HCC 11. Subsequently, 
another study by the same authors suggested that rs7574865 is associated with the risk of cirrhosis 
based on computed tomography (CT) or ultrasonography in 712 Chinese patients with CHB 13. 
However in that study, liver histology data were not available and hence, associations to earlier disease 
stages or to inflammation could not be discerned. Apart from demonstrating for the first time 
significant associations with hepatic inflammation grade and fibrosis stage, we observed a higher 
frequency of the risk (G) allele in Caucasians with CHB suggesting a role for this genetic variation in 
HBV persistence. In Asian populations, it has been reported that the GG genotype is more likely to 
have a lower rate of HBeAg seroconversion as well as response to IFN-α therapy than those with the 
(GT/TT) genotype (again, liver histology was not available) 12. Hence, several levels of evidence in 
addition to the current data reinforce the notion that STAT4 is pivotal in determining the outcome of 
HBV infection.  
 In patients with CHB, NK cells exhibit a dichotomy in effector functions characterized by 
conserved or enhanced cytolytic activity but at the same time, reduced IFN-γ production 23. The latter is 
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a major determinant of the anti-viral and anti-fibrotic capabilities of NK cells 23 and a determinant of 
immunomodulatory regulatory T cell (Treg) recruitment to the liver 25. Thus, NK cell-derived IFN-γ 
plays a key role in promoting HBV viral clearance, 26 while it inhibits stellate cell activation and 
enhances NK cell cytotoxic activity towards these cells 22, 27, 28. NKT cell-derived IFN-γ also triggers 
secretion of chemokine (C-X-C motif) ligand 10 (CXCL10) that in turn attracts Tregs to limit hepatic 
inflammation 25. These functional data are supported by a recent study suggesting that IFN-γ 
production by intrahepatic NK cells is reduced in patients with advanced HBV-related liver fibrosis 29. 
Notably, the ability of NK cells to produce IFN-γ in response to IL-12 is dependent on STAT4 
phosphorylation 30. 
 Aside from genetic association studies, detailed functional mechanisms by which the STAT4 
rs7574865 variant contributes to CHB pathogenesis is unknown. In this work we extend knowledge to 
include functional genomics, demonstrating that the (G) risk allele is associated with lower STAT4 
mRNA expression in liver and PBMCs, reduced STAT4 phosphorylation and reduced production of 
IFNγ by NK cells following ex-vivo stimulation. These effects likely contribute to impaired NK cell 
antiviral immune responses leading to virus persistence, and to the promotion of liver fibrosis and 
inflammation. The latter likely explains the negative correlations to indicators of liver cell injury and 
histological inflammation score that we observed. In support, knockout of STAT4 renders mice 
susceptible to concanavalin A-induced hepatitis 8, lethal endotoxemia 31, and pancreatitis-associated 
lung injury32.  
   Another highlight of the present study is the differential role of rs7574865 in HBV and HCV 
infected Caucasian patients. In a recent study, we did not observe any association between rs7574865 
genotype and spontaneous HCV viral clearance, response to IFN-α therapy, fibrosis severity or fibrosis 
progression (n=1211)15. At present it is not clear why STAT4 rs7574865 predicts liver injury only in 
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patients with CHB. Interestingly, in work utilizing laser capture microdissection from liver of patients 
with CHB and CHC, it was shown that STAT3, which has high amino acid sequence homology to 
STAT4 33, was strongly upregulated in CHB, when compared to CHC 34. STAT3 is a major mediator of 
HCC risk and suggests that the role of the JAK/STAT pathway in the tumorigenic process in CHB and 
CHC may differ.  
 In conclusion, we show that STAT4 genetic variation at rs7574865 is associated with greater 
hepatic inflammation and fibrosis in Caucasian patients with chronic HBV infection; this effect is at 
least in part regulated by STAT4 expression and phosphorylation that differentially modulates IFNγ 




FIGURE LEGENDS  
 
Figure 1: Association of STAT4 rs7574865 genotypes with (A) inflammation degree and B) 
fibrosis stage (n=830). The rate of moderate/severe hepatic inflammation (METAVIR A2-A3) and 
advanced fibrosis (METAVIR F3-F4) is shown according to rs7574865 genotype. Numbers per each 
genotype is in parentheses under the genotype. P-values are univariate and provided for the recessive 
model of inheritance.   
Figure 2: STAT4 expression is decreased in patients with HBV infection and in HBV-expressing 
cells. A) Comparison of hepatic STAT4 mRNA levels in hepatitis B patients (n=45) and controls 
(n=28). B) qRT-PCR was used to determine the HBV copy numbers in Huh-7 cells transiently 
transfected with plasmid HBV/Dw or control vector. C) mRNA levels of STAT4 in Huh-7 cells 
transiently transfected with plasmid HBV/Dw relative to GAPDH by qRT-PCR. D) Hepatic STAT4 
mRNA levels according to hepatic inflammation score. The x axis represents hepatic inflammation 
dichotomized as absent/mild (METAVIR score A0-A1) (n=15) or moderate/severe (METAVIR score 
A2-A3) (n=30), and the y axis represents hepatic STAT4 expression relative to GAPDH by qRT-PCR. 
The number of independent samples tested in each group is shown in parentheses. Data are shown as 
median and interquartile range or mean and sem and the P-value was calculated using the two-tailed 
Mann–Whitney test or t-test. E) STAT4 mRNA expression in human primary hepatic cells types. Gene 
expression level was measured as number of copies/50 ng of total RNA by ultrasensitive droplet digital 
PCR (ddPCR) ddPCR. KC, kupffer cells; HH, human hepatocytes; HHSEC, human hepatic sinusoidal 
endothelial cell; HSC, hepatic stellate cells. 
Figure 3: STAT4 expression according to rs7574865 genotype in liver and peripheral blood 
mononuclear cells (PBMCs). A) Association between STAT4 rs7574865 genotype and hepatic STAT4 
mRNA levels (n=45). The x axis shows the genotype at rs7574865 using a recessive model (GG versus 
GT/TT) (GG=28, GT/TT=17) and the y axis shows STAT4 expression level relative to GAPDH by 
qRT-PCR. B) Association between STAT4 rs7574865 genotype and PBMC STAT4 mRNA levels 
(n=30). The x axis shows the genotype at rs7574865 using a recessive model (GG versus GT/TT) 
(GG=16, GT/TT=12) and the y axis shows STAT4 expression level relative to GAPDH by qRT-PCR. 
C) Summary of basal STAT4 levels in natural killer (NK) cells from subjects with the GG genotype 
(n=10) and GT/TT (n=10) as determined by flow cytometry. The mean fluorescence intensity of 
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STAT4 is plotted. D) Representative flow cytometry histograms showing interleukin (IL) 12 and 18 
stimulated pSTAT4 staining in subjects with GG and GT/TT genotype. E) Summary of pSTAT4 
inducibility reflects the pSTAT4 MFI of NK cells after in vitro stimulation of PBMCs with IL1-2/IL-18 
normalized to the respective MFI of unstimulated cells in subjects with GG (n=7) and GT/TT 
genotypes (n=7). The number of independent samples tested in each group is shown in parentheses. 
Data are shown as median and interquartile range or mean; P-value was calculated using the two-tailed 
Mann–Whitney test. 
Figure 4: The rs7574865 GG risk genotype has decreased pSTAT4- dependent IFN-γ production 
by NK cells. A) Frequency of NK cells that produced IFN-γ in response to in vitro stimulation with IL-
12 and IL-18 was measured by flow cytometry and B) the increase in production of IFN-γ by 
stimulated NK cells over unstimulated cells was quantified in the supernatants by ELISA. Charts show 
median and interquartile range; the P-value was calculated using the two-tailed Mann–Whitney test. 
Figure 5: Postulated mechanism based on the present study for the role of STAT4 rs7574865 





Table 1. Independent predictors of severe inflammation (≥A2) and advanced fibrosis (≥F3) by logistic 
regression analysis in the HBV patient cohort (n=830).  
 Severe inflammation (≥A2) Advanced fibrosis (≥F3) 
 OR 95% CI P- value OR 95% CI P- value 
Age, years 1.01 1.001-1.03 0.03 1.06 1.04-1.08 0.0001 
Gender, male  1.41 0.94-2.11 0.08 1.63 1.03-2.6 0.03 
BMI, Kg/m
2
 1.07 1.02-1.13 0.02 1.05 1.004-1.11 0.03 
HBV-DNA (Log10 IU/mL) 1.08 0.99-1.17 0.057 1.13 1.03-1.24 0.01 
STAT4 rs7574865 1.42 1.07-2.06 0.02 1.83 1.19-2.83 0.006 
 
Genetic analyses were undertaken using a recessive model as previously reported. OR: odds ratios, 95% CI: 
95% confidence interval. Multiple Logistic regression models were used to test the association of STAT4 
rs7574865 with liver histology outcomes (inflammation and fibrosis). In addition to predictors shown here, 
models were adjusted for recruitment centre. For rs7574865 analysis, a recessive model (GG versus GT/TT) was 
adopted as reported previously in the literature because the GG genotype was found to be the only risk genotype 
in the recent HBV-related HCC GWAS. The reference group was defined by absent/mild (METAVIR score A0-
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